13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002005245
Total reported value
$4.9B
$4.9B
110 檔
10.4%
At the close of Q3 2024, Siren, L.L.C. disclosed equity holdings valued at approximately $4.9B, spread across 110 reported holdings.
During Q3 2024, Siren, L.L.C.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including KYMR, ONC, SRRK) accounted for 10.4% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics Inc | Stock-Other | 7.03% | -0.55% | — | |
| 2 | ONC | Beone Medicines Ltd-adr | Stock-Other | 6.32% | -1.15% | — | |
| 3 | SRRK | Scholar Rock Holding CORP | Stock-Other | 4.51% | -4.09% | — | |
| 4 | BCAX | Bicara Therapeutics Inc | Stock-Other | 3.91% | +0.17% | — | |
| 5 | ARGX | Argenx Se - Adr | Stock-Healthcare | 3.89% | — | — | |
| 6 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.35% | -0.84% | — | |
| 7 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.31% | — | — | |
| 8 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.12% | — | — | |
| 9 | LXRX | Lexicon Pharmaceuticals Inc | Stock-Other | 3.05% | +0.23% | — | |
| 10 | 1K0 | Igm Biosciences Inc | Stock-Other | 2.75% | — | — | |
| 11 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.60% | -1.16% | EXIT | |
| 12 | ASND | Ascendis Pharma A/S | Stock-Other | 2.60% | — | — | |
| 13 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 2.57% | +0.31% | — | |
| 14 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 2.38% | +0.02% | — | |
| 15 | WVE | Wave Life Sciences Ltd. | Stock-Other | 2.35% | -0.49% | EXIT | |
| 16 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 2.21% | — | — | |
| 17 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.04% | -0.16% | — | |
| 18 | VERA | Vera Therapeutics Inc | Stock-Other | 1.85% | — | — | |
| 19 | NMRA | Neumora Therapeutics Inc | Stock-Other | 1.72% | -0.17% | — | |
| 20 | PCVX | Vaxcyte Inc | Stock-Other | 1.71% | — | — | |
| 21 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.71% | +0.41% | — | |
| 22 | ✓ | Merus N V | Stock-Other | 1.70% | — | — | |
| 23 | TBLA | Taboola.com Ltd. | Stock-Other | 1.67% | -0.01% | — | |
| 24 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 1.50% | — | — | |
| 25 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.46% | -0.52% | — | |
| 26 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.39% | +0.19% | — | |
| 27 | KURA | Kura Oncology Inc | Stock-Other | 1.31% | — | — | |
| 28 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.23% | -0.29% | — | |
| 29 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.21% | -0.01% | — | |
| 30 | ERAS | Erasca Inc | Stock-Other | 1.21% | -0.81% | — | |
| 31 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 1.01% | +0.23% | — | |
| 32 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.00% | +0.63% | — | |
| 33 | SLDB | Solid Biosciences Inc | Stock-Other | 0.96% | +0.02% | — | |
| 34 | PRTA | Prothena Corporation plc | Stock-Other | 0.92% | — | — | |
| 35 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.76% | — | — | |
| 36 | BHVN | Biohaven Ltd. | Stock-Other | 0.71% | — | — | |
| 37 | KRRO | Korro Bio Inc | Stock-Other | 0.70% | -0.02% | — | |
| 38 | APLT | Applied Therapeutics Inc | Stock-Other | 0.69% | — | — | |
| 39 | GOSS | Gossamer Bio Inc | Stock-Other | 0.67% | -0.03% | — | |
| 40 | TIL | Instil Bio Inc | Stock-Other | 0.65% | — | — | |
| 41 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.54% | -1.25% | — | |
| 42 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 0.52% | — | — | |
| 43 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.52% | -0.39% | — | |
| 44 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.50% | — | — | |
| 45 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.49% | +0.27% | — | |
| 46 | MSFT | Microsoft CORP | Stock-Tech | 0.47% | +0.04% | — | |
| 47 | RNAC | Cartesian Therapeutics Inc | Stock-Other | 0.46% | — | — | |
| 48 | ✓ | Acelyrin Inc | Stock-Other | 0.43% | — | — | |
| 49 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 0.42% | — | — | |
| 50 | SEER | Seer Inc | Stock-Other | 0.39% | -0.03% | — |
According to official SEC Form 13F filings, Siren, L.L.C. reported a total U.S. public equity portfolio value of $4.9B across 110 disclosed positions in Q3 2024.
During Q3 2024, Siren, L.L.C.'s top holdings by market value included KYMR (7.0%)、ONC (6.3%)、SRRK (4.5%). The largest single position, KYMR, represented 7.0% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q3 2024, Siren, L.L.C. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.